| References: |
Regorafenib is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of Regorafenib (BAY 73-4506, Fluoro-Sorafenib) in water, the solubility of Regorafenib (BAY 73-4506, Fluoro-Sorafenib) in DMSO, the solubility of Regorafenib (BAY 73-4506, Fluoro-Sorafenib) in PBS buffer, the animal experiment（test） of Regorafenib (BAY 73-4506, Fluoro-Sorafenib),the in vivo,in vitro and clinical trial test of Regorafenib (BAY 73-4506, Fluoro-Sorafenib),the cell experiment（test） of Regorafenib (BAY 73-4506, Fluoro-Sorafenib),the IC50, EC50 and Affinity of Regorafenib (BAY 73-4506, Fluoro-Sorafenib), please contact DC Chemicals. |
